62 related articles for article (PubMed ID: 10582694)
1. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.
Toretsky JA; Thakar M; Eskenazi AE; Frantz CN
Cancer Res; 1999 Nov; 59(22):5745-50. PubMed ID: 10582694
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.
Li Q; Li Z; Luo T; Shi H
Mol Biomed; 2022 Dec; 3(1):47. PubMed ID: 36539659
[TBL] [Abstract][Full Text] [Related]
4. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
5. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma.
Jin W
Front Cell Dev Biol; 2020; 8():613. PubMed ID: 32754598
[TBL] [Abstract][Full Text] [Related]
6. Destined to Die: Apoptosis and Pediatric Cancers.
Choo Z; Loh AHP; Chen ZX
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652776
[TBL] [Abstract][Full Text] [Related]
7. Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.
Casey DL; Lin TY; Cheung NV
Front Oncol; 2019; 9():537. PubMed ID: 31275859
[TBL] [Abstract][Full Text] [Related]
8. Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel
Slotkin EK; Diolaiti D; Shukla NN; Dela Cruz FS; Clark JJ; Gundem G; Yellapantula VD; Levine MF; You D; Ma P; Pachhal S; Ibanez Sanchez G; Benayed R; Jungbluth AA; Smyth LM; Mauguen A; Gushterova I; Ding H; Spraggon L; Darnell R; Califano A; Ladanyi M; Papaemmanuil E; Kung AL; Hyman DM; Roberts SS
Cancer Discov; 2019 May; 9(5):605-616. PubMed ID: 30877085
[TBL] [Abstract][Full Text] [Related]
9. miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways.
Zhang S; Li D; Jiao GJ; Wang HL; Yan TB
Onco Targets Ther; 2018; 11():7967-7977. PubMed ID: 30519038
[TBL] [Abstract][Full Text] [Related]
10. miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Ye C; Yu X; Liu X; Dai M; Zhang B
Oncol Lett; 2018 Apr; 15(4):4390-4396. PubMed ID: 29541208
[TBL] [Abstract][Full Text] [Related]
11. PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways.
Lv D; Liu J; Guo L; Wu D; Matsumoto K; Huang L
Am J Cancer Res; 2016; 6(2):486-97. PubMed ID: 27186418
[TBL] [Abstract][Full Text] [Related]
12. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.
Patel M; Gomez NC; McFadden AW; Moats-Staats BM; Wu S; Rojas A; Sapp T; Simon JM; Smith SV; Kaiser-Rogers K; Davis IJ
Mol Cancer Res; 2014 Nov; 12(11):1610-20. PubMed ID: 24994750
[TBL] [Abstract][Full Text] [Related]
13. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
14. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.
Loh AH; Brennan RC; Lang WH; Hickey RJ; Malkas LH; Sandoval JA
Front Oncol; 2013; 3():93. PubMed ID: 23638435
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.
O'Neill A; Shah N; Zitomersky N; Ladanyi M; Shukla N; Uren A; Loeb D; Toretsky J
Sarcoma; 2013; 2013():450478. PubMed ID: 23431249
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
[TBL] [Abstract][Full Text] [Related]
18. A Novel Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells.
van Valen F; Harrer H; Hotfilder M; Dirksen U; Pap T; Gosheger G; Humpf HU; Jürgens H
Sarcoma; 2012; 2012():782970. PubMed ID: 23091403
[TBL] [Abstract][Full Text] [Related]
19. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
20. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
